SCHEMBL17679286

SCHEMBL17679286

CC(C)(C)C(=O)c1sccc1-c1ncccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 3/20 0.39
HCRTR1 O43613 2/20 0.39
RORB Q92753 3/20 0.36
RORC P51449 2/20 0.36
BCAT2 O15382 1/20 0.36
LMNA P02545 2/20 0.35
NPC1 O15118 5/20 0.35
RAB9A P51151 5/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PPARG P37231 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
TP53 P04637 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PKM P14618 1/20 0.35
METAP1 P53582 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18197671 0.81 ALDH1A1 (0.44) HCRTR2HCRTR1RORBRORCBCAT2
SCHEMBL16011605 0.78 BCAT2 (0.59) HCRTR2HCRTR1RORBRORCBCAT2
SCHEMBL17681955 0.77 ADORA2A (0.39) HCRTR2HCRTR1BCAT2LMNANPC1
SCHEMBL6198432 0.75 HDAC1 (0.49) BCAT2LMNANPC1RAB9AKMT2A
SCHEMBL17863861 0.74 HCRTR2 (0.44) HCRTR2HCRTR1
SCHEMBL17448835 0.73 HCRTR2 (0.43) HCRTR2HCRTR1KMT2A
SCHEMBL17448840 0.71 KDM4E (0.39) HCRTR1LMNAMAPT
SCHEMBL12666536 0.70 GSK3B (0.53) LMNANPC1RAB9APPARGNCOR2
SCHEMBL17885701 0.69 HCRTR2 (0.43) HCRTR2HCRTR1LMNAMAPT
SCHEMBL10110869 0.68 MAPT (0.50) RORBLMNAKMT2APKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9617246-B2 Thioether-piperidinyl orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-04-11 US disclosed
US-9617246-B2 Thioether-piperidinyl orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-04-11 US disclosed
US-9586934-B2 2-pyridyloxy-4-methyl orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-03-07 US disclosed
US-9586934-B2 2-pyridyloxy-4-methyl orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-03-07 US disclosed
US-20160368898-A1 2-PYRIDYLOXY-4-METHYL OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-12-22 US disclosed
US-20160318899-A1 THIOETHER-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-11-03 US disclosed
US-20160102073-A1 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318899-A1 THIOETHER-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR HCRTR2 1/4885HCRTR1 2/4885RORB 214/4885
US-20160368898-A1 2-PYRIDYLOXY-4-METHYL OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY2R HCRTR2 1/4885HCRTR1 2/4885RORB 217/4885
US-20160102073-A1 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CRHR2 HCRTR2 1/4885HCRTR1 2/4885RORB 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.